Clinical Trials Browser

OTHER × Interventional × Paraganglioma × Clear all

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Phase 1 Recruiting

BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT03946527 2026-03-02

LAMPARA

Phase 2 Active not recruiting

Paraganglioma, Pheochromocytoma

NCT05636540 2026-02-27

In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma

Phase EARLY_PHASE1 Recruiting

Paraganglioma, Pheochromocytoma

NCT04081701 2025-11-21

DOMINO-START

Phase 4 Recruiting

Medulloblastoma, Meningioma, Paraganglioma, Pituitary Neoplasms, Central Nervous System Neoplasms, Esthesioneuroblastoma, Olfactory, Hemangioblastoma

NCT07167329 2025-09-11

BELIEVE-VHL

Phase 2 Recruiting

CNSEndocrineGenitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma, Neuroectodermal Tumors, Primitive, Hemangioblastoma

NCT06683846 2025-08-24

Ivonescimab in the Treatment of Multiple Advanced Tumors

Phase 2 Recruiting

CNSDermatologicEndocrineGenitourinarySarcoma

Urachal cancer, Carcinoma, Carcinoma, Basal Cell, Carcinoma, Transitional Cell, Kidney Neoplasms, Paget Disease, Extramammary, Paraganglioma, Penile Neoplasms, Pheochromocytoma, Prostatic Neoplasms, Rhabdomyosarcoma, Sarcoma, Angiomyolipoma, Carcinoma, Neuroendocrine, Perivascular Epithelioid Cell Neoplasms

NCT06377033 2025-07-20

Using the EHR to Advance Genomic Medicine Across a Diverse Health System

Phase NA Recruiting

Alzheimer Disease, Paraganglioma, Parkinson Disease, Pheochromocytoma, Polyneuropathies, Aortic Aneurysm, Thoracic, Genetic Predisposition to Disease, Frontotemporal Dementia

NCT04400474 2025-06-19

CABATEN

Phase 2 Completed

93 enrolled 17 charts

CNSEndocrineHead & NeckNET

Adenocarcinoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors, Thyroid Carcinoma, Anaplastic

NCT05702944 2025-06-12

The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma

Phase 4 Recruiting

Paraganglioma, Pheochromocytoma

NCT06607692 2024-10-21

LUPARPED

Phase 2 Recruiting

CNSEndocrineNET

Adrenal Gland Neoplasms, Medulloblastoma, Meningioma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT06045260 2024-08-13

LUFOR

Phase 2 Recruiting

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT04605848 2024-05-09

MICROBAT

Phase NA Terminated

Paraganglioma, Pheochromocytoma

NCT05069220 2024-03-01

18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor

Phase EARLY_PHASE1 Recruiting

CNSEndocrineNET

Neuroblastoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT03176693 2023-11-20

Preoperative Alpha Blockade for Pheochromocytoma

Phase 3 Completed

39 enrolled 8 charts

Paraganglioma, Pheochromocytoma

NCT05885386 2023-06-01

A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL

Phase 2 Unknown

Paraganglioma, Pheochromocytoma

NCT05883085 2023-05-31

A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL

Phase 2 Unknown

Paraganglioma, Pheochromocytoma

NCT02186678 2023-04-06

DOTATATE

Phase NA Completed

Paraganglioma, Pheochromocytoma

NCT00442533 2023-04-03

Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors

Phase 2/3 Completed

CNSEndocrineNET

Carcinoid Tumor, Paraganglioma, Pheochromocytoma, Somatostatinoma, Neuroendocrine Tumors

NCT04276597 2023-03-10

PUTNET

Phase 2 Withdrawn

CNSDermatologicEndocrineNET

Neoplasms, Unknown Primary, Paraganglioma, Pheochromocytoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT01371201 2022-08-04

FIRSTMAPPP

Phase 2 Completed

Paraganglioma

NCT05133349 2021-11-24

EASOAIPPGL

Phase 2 Unknown

Paraganglioma, Pheochromocytoma

NCT03923257 2021-06-08

Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents

Phase 1/2 Withdrawn

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT04106843 2020-09-07

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

Phase 2 Withdrawn

CNSEndocrineHead & Neck

Paraganglioma, Parathyroid Neoplasms, Pheochromocytoma, Pituitary Neoplasms, Carcinoma, Medullary

NCT01347307 2020-06-18

Stereotactic Body Radiotherapy for Spine Tumors

Phase NA Completed

38 enrolled 11 charts

CNSEndocrineSarcoma

Arteriovenous Malformations, Chordoma, Meningioma, Neurilemmoma, Neurofibroma, Paraganglioma

NCT04029428 2020-04-01

POLNETS_PRRT

Phase 2 Unknown

CNSEndocrineNET

Paraganglioma, Neuroendocrine Tumors

NCT02177773 2019-11-12

DOTA-TOC

Phase 1/2 Terminated

300 enrolled 5 charts

CNSEndocrineNET

Carcinoid Tumor, Neuroblastoma, Paraganglioma, Neuroendocrine Tumors

NCT02672020 2019-09-24

COMETETACTIC

Phase NA Completed

Adrenal Gland Neoplasms, Paraganglioma, Pheochromocytoma, Adrenocortical Carcinoma

NCT01413503 2018-09-18

A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors

Phase 2 Completed

50 enrolled 7 charts

Neoplasms, Paraganglioma, Pheochromocytoma, Recurrence